Background: A prolonged activated partial thromboplastin time (APTT) of unknown
| INTRODUCTION
The past 3 decades have witnessed tremendous improvements in our understanding about hemostasis and in our technical capability to scale up the measurement of coagulation and platelet function in clinical laboratories. However, the pace of these technical developments frequently outruns our capacity to generate data about the clinical and financial impact of the incorporation of these technologies in patient care. The activated partial thromboplastin time (APTT) and prothrombin time (PT) are screening assays indicated for the initial assessment of disorders of hemostasis. Although these assays have been described for several decades, recent improvements of coagulation automated analyzers now available in most clinical laboratories led to their widespread use, even in conditions in which their indication is not clear. 1 The APTT is a coagulometric assay in which platelet-poor plasma is stimulated by a reagent containing phospholipids, an activator (eg, ellagic acid, silica), and calcium chloride. The time to fibrin formation, measured by optical or mechanical methods is dependent on the concentration and/or function of coagulation factors of the intrinsic and final pathways of the coagulation cascade, as well as on the presence of specific (ie, against discrete coagulation factors) or nonspecific (ie, against antiphospholipids) inhibitors to components of the reaction. In addition to preanalytical variables, which are known to strongly influence all plasma-based assays of hemostasis, differences in APTT sensitivity dependent on the phospholipid composition and the type of activator used in different APTT reagents are also a cause of significant imprecision of this assay, 2,3 a fact that supports the recommendation that laboratories should establish reagent-specific reference ranges. 4 Accordingly, the potential impact of these variables (ie, preanalytical and reagent-specific sensitivity) should be acknowledged when results are interpreted in the clinical setting.
Although the APTT was developed as a tool to aid in the diagnosis of hemophilia, 5 it is also indicated to evaluate or monitor patients with other disorders of hemostasis (affecting the intrinsic and common final pathways of the coagulation cascade) and in the monitoring of therapy with unfractionated heparin. 6 However, this assay is also used for less clear-cut indications such as the investigation of consumptive coagulopathies 7 and in preoperative screening. 8 As mentioned above, it has recently been demonstrated that a high proportion of APTT requests are not supported by evidence, even in academic medical centers. 1 Despite the use of the APTT for several decades in nearly all medical services, to our knowledge only 1 study systematically addressed the relative contribution of different conditions known to prolong this test in a population of outpatients referred to hemostasis consultation, which represents a common clinical problem faced by hematologists. Herein, we consecutively evaluated all cases of APTT prolongation in an outpatient hemostasis laboratory during a 14-year period, thereby providing data on the relative contribution of different conditions for APTT prolongations. We also describe the resources used to investigate these results and discuss the financial impact thereof.
| METHODS

| Study population
The study was designed as a retrospective cohort study performed in the outpatient hemostasis clinic of the University of Campinas, which is the only service that provides specialized consultation in hemostasis for an area of around 6 million inhabitants in southeastern APTT ratio >1.30 was used as a threshold to initially screen for cases from our laboratory database. Because the aim of our study was to describe the distribution of conditions causing a prolonged APTT in this specific outpatient setting (ie, patients referred for diagnostic evaluation of a prolonged APTT), only cases in which the APTT prolongation was confirmed in the first visit were included. In addition, all cases in which the diagnosis of a hereditary bleeding disorder was established before patient referral (eg, patients with a confirmed diagnosis of factor VIII [FVIII] or factor IX [FIX] deficiencies referred to our hemophilia unit) or patients referred due to a diagnosis of conditions known to be associated with prolonged APTT (eg, patients referred for unfractionated heparin monitoring) were also excluded from the analysis.
| Data collection and investigation protocols
Clinical and laboratory data were obtained from the electronic medical records of our institution. In the first visit, the APTT was repeated
Essentials
• Prolonged activated partial thromboplastin time (APTT) is one of the most common reasons for hematology consultation.
• In this scenario, the main causes of prolonged APTT are not associated with increased bleeding risk.
• Antiphopholipid antibodies represent the main cause of APTT prolongation in outpatients.
• In conclusion, our data reinforce the importance of rational use of this common screening assay.
in our laboratory, along with a PT. Mixing studies were performed in the same sample in all cases with a prolonged APTT, and these results were available for the medical evaluation. A detailed clinical history and physical examination focused on bleeding and thrombotic events was then obtained. Standardized bleeding scores 9 were used at the attending physician's discretion until 2012 and systematically thereafter. No other significant change was introduced in patient management during the study period, except for improvements in the quality of laboratory reagents. Additional laboratory assays were requested according to the clinical presentation until a confirmatory diagnosis was obtained.
| Laboratory measurements
All assays were performed in the hemostasis laboratory of our 
| Financial impact analysis
We next evaluated the use of additional laboratory resources in the investigation of prolonged APTT. The number of specific assays was individually counted per patient. The cost in US dollars was estimated using 2 Brazilian national reimbursement tables: (1) (2) costs from a reference private hemostasis laboratory that provides services for the whole country. 187 patients eligible for the final analysis distribution. A P value <0.05 was considered as statistically significant. All analyses and graphs were performed using Prism 7.0 (GraphPad Software, La Jolla, CA).
| RESULTS
Between September 2003 and April 2017, a total of 7983 prolonged
APTTs were released by the hemostasis laboratory of the University of Campinas. After exclusion of repetitions from the same patient, a total of 2468 results were identified. Of these, 941 results were from 941 patients in the first visit to our hemostasis outpatient clinic, with the remaining results corresponding to patients who were already followed in our center with a known diagnosis. Of these, 754 patients were excluded because they were referred with a definitive diagnosis associated with APTT prolongation such as hemophilia or unfractionated heparin use. In total, 187 patients who were specifically referred to our clinic to investigate a confirmed prolongation of APTT on unknown etiology were included in our study. A detailed flowchart is shown in Figure 1 .
The main clinical and demographic characteristics of study patients are shown in Table 1 . Of note, approximately half of the patients reported the presence of at least 1 bleeding symptom at the first evaluation, although the median bleeding score 9 was low in the majority of patients.
The distribution of the APTT ratio (R-APTT) ranged from 1. The relative distribution of these causes and their relative distribution according to age and the presence of bleeding symptoms are shown in Table 2 .
We also investigated whether this pattern of causes remained stable throughout the whole study, which was divided into 3 periods for this analysis. As shown in Figure 3 , except for a clear increase in the proportion of cases attributed to the presence of APLs, other causes remained stable through time.
We next compared the magnitude of APTT prolongation be- Finally, we evaluated resource used for each patient until a definite cause for APTT prolongation could be established. As shown in Table 3 , each case required a mean of 16.8 (standard deviation, 11.2) additional assays during the etiological investigation.
In Table 4 , the financial impact of the additional laboratory investigation for a prolonged APTT was estimated based on the number of assays required, according to the reference costs for 2 different categories of health care providers in Brazil: the cost suggested for reimbursement of laboratories by private health care insurance companies 14 and costs charged by the laboratory by 1 reference private laboratory. 15 Estimated costs with additional laboratory assays varied between US$157.40 and US$887.10.
| DISCUSSION
Despite being one of the most widely used hemostasis screening assays, few data are available on the causes of prolonged APTT in patients referred for hematologic consultation. To our knowledge, only 1 study, published more than 30 years ago, described the relative contribution of different causes of APTT prolongation among 100 patients referred for hemostasis consultation. 16 The main result of our study was a contemporary description of causes of prolonged APTT in 187 outpatients from an academic Causes of prolonged APTT have been previously described in 2 different scenarios. In a study that included 177 inpatients from a general hospital, the main cause of prolonged APTT was the presence of LA, detected in 53.1% of patients, followed by undetermined causes in 31.6%. Factor deficiencies were rare, with those associated with bleeding risk observed in only 4.5%. 17 However, these results cannot be extrapolated to outpatients. In a study performed in a clinical scenario similar to ours, Kitchens 16 described causes of APTT prolongation in 100 consecutive patients referred for hemostasis consultation. The most frequent cause was the presence of an LA (33% of patients), followed by liver disease/vitamin K deficiency (9%). Coagulation factor deficiencies associated with bleeding risk were observed in 50% of patients, and FXII deficiency in only 2%. 18 In the 3 decades since this publication, the quality of equipment and reagents used in hemostasis laboratories has improved, and accessibility to hemostasis assays has increased, leading to gains in accuracy of these assays and to an increase in the number of patients for whom an APTT was ordered. We therefore hypothesized that the pattern of distribution of causes for prolonged APTT also could have changed. In addition, we wanted to estimate the financial impact of these investigations. In regard to the first hypothesis, although the presence of APL (which in our study included all patients with a positive LA in at least 2 independent samples) was still the main cause of prolonged APTT, contact pathway factor deficiencies emerged as the third most frequent cause, and a definitive explanation for the prolonged APTT could not be obtained in 22.1% of patients despite a comprehensive investigation. Because the former 2 conditions are not associated with bleeding symptoms, our results indicate that in at least 60% of cases, the clinical benefit of the extensive investigation that follows an index APTT prolongation is not clear. Previously undiagnosed liver disease was also an important cause of APTT prolongation (in nearly 10% of patients). Of note, although we included only patients in whom the APTT prolongation was confirmed in a second sample, normalization of the APTT still occurred in almost 5% of cases, highlighting the importance of repeating the assay in the course of the investigation.
As for the 22.1% of patients in whom a defined cause of APTT prolongation was not identified, most were <12 years old and asymptomatic. We list several potential reasons to explain these cases. APLs, antiphospholipid antibodies (defined as the presence of a lupus anticoagulant in 2 independent samples); APTT, activated partial thromboplastin time. to the effect of APLs (and also of some cases with severe contact factor deficiencies), which are responsible for higher R-APTT values in our population, as these patients tend to be asymptomatic and are less likely to remain undiagnosed. However, the overlap of R-APT across all categories precludes inferences about etiologic diagnoses based on this assay. 23 We also feel that all prolonged APTTs that are not associated with a clinical history of bleeding should be confirmed before pursuing further workup.
Our study has limitations that should be acknowledged. First, the retrospective design is associated with inherent limitations such as incomplete information and variations in patients' care. However, the fact that our outpatient clinic is part of an academic medical center limits the impact of these biases, as investigation protocols are strictly followed by our medical staff. The availability of electronic medical records and the stepwise protocol used to identify cases also limit the possibility of missing information. Second, we included only patients with a confirmed APTT prolongation, which precluded the discussion on the proportion of cases in which the prolongation is caused by laboratory errors (preanalytical, analytical, and postanalytical). While of interest to most clinicians, the contribution of these errors is dependent mainly on the quality of clinical and laboratory care of referring centers, so that results from a single center are difficult to generalize. We therefore focused on the description of cases with sustained APTT prolongations, which represent a welldefined cohort of patients, prevalent in most hemostasis services.
Changes in laboratory equipment and reagents during the study are also worth considering, although as our study aimed to capture clinical practice, this limitation should also be considered acceptable. Of note, our laboratory has been part of international external quality systems throughout most of the study period and constantly updates its protocols in accordance with major international guidelines.
Finally, it is important to acknowledge that since the standardized bleeding questionnaire was not introduced as a routine in our center until after 2012, the associations involving the presence of bleeding symptoms should be evaluated with caution.
In conclusion, our study provides contemporary data on the relative distribution of causes for APTT prolongation in one of the most common clinical scenarios of consultative hemostasis, confirming
APLs as the main cause of this laboratory alteration, and highlighting the significance of a prolonged APTT in the absence of a specific disease of hemostasis. We also provide evidence supporting the importance of measures to minimize the indiscriminate use of these assays, to avoid the inadequate use of the finite resources available for our health systems.
